Neuroimaging and CSF Biomarker Program

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

• Developing novel PET ligands for clinical trials
• Supporting novel CSF biomarkers
• Validating innovative MRI approaches in larger cohorts
• Developing novel measures of functional activity such as EEG

Peripheral biofluids and digital/ocular approaches are supported through the Diagnostics Accelerator RFP.

Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:

• Neuronal loss
• Vascular injury and blood-brain barrier integrity
• Mitochondria and metabolic function
• Protein misfolding
• Oxidative stress
• White matter changes
• Lewy body dementia
• Other novel targets supported by compelling biological rationale and connection to disease

Eligibility

Funding is open to researchers and clinicians worldwide at:

• Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
• Biotechnology companies. Existing companies and new startups are both eligible.
• NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).

Timeline

Letter of Intent:

February 4, 2022
May 20, 2022
September 30, 2022

Full Proposal:

April 8, 2022
July 22, 2022
December 2, 2022

See Full Eligibility & Application Details